PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-18.62%
Cash & equivalents declining -18.62% while Medical - Pharmaceuticals shows -6.07% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-18.62%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of -3.68%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
No Data
No Data available this quarter, please select a different quarter.
-1.84%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
4.70%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-8.20%
Below half the Medical - Pharmaceuticals median of 0.42%. Jim Chanos would question if the company faces working capital strain.
4.72%
PP&E growth ≥ 1.5x the Medical - Pharmaceuticals median of 0.42%. Joel Greenblatt sees aggressive expansion. Check if revenue growth supports it.
No Data
No Data available this quarter, please select a different quarter.
36.54%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
36.54%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
2.32%
Above 1.5x Medical - Pharmaceuticals median of 0.25%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
4.24%
≥ 1.5x the Medical - Pharmaceuticals median of 0.72%. Joel Greenblatt sees more aggressive long-term asset growth than peers, but it must be value-accretive.
No Data
No Data available this quarter, please select a different quarter.
-1.83%
Below half the Medical - Pharmaceuticals median of 1.31%. Jim Chanos might see potential stagnation or distress vs. peers.
-4.03%
Payables growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a warning sign of stressed supplier payments.
-5.94%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a short-term leverage spike, raising red flags for near-term solvency.
-38.55%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-38.28%
≥ 1.5x the Medical - Pharmaceuticals median of -0.01%. Joel Greenblatt sees a robust subscription base vs. peers.
2.22%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-5.39%
Below half Medical - Pharmaceuticals median of 3.85%. Joel Greenblatt sees more conservative short-term leverage than peers.
-13.18%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
3.72%
Above 1.5x Medical - Pharmaceuticals median of 1.99%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-5.62%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-5.42%
Below half Medical - Pharmaceuticals median of 1.84%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
7.29%
≥ 1.5x Medical - Pharmaceuticals median of 1.97%. Joel Greenblatt sees stronger retained profit growth vs. peers.
No Data
No Data available this quarter, please select a different quarter.
50.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential red flag for complicated equity transactions.
4.96%
≥ 1.5x Medical - Pharmaceuticals median of 1.21%. Joel Greenblatt sees stronger equity growth vs. peers.
-1.83%
Below half Medical - Pharmaceuticals median of 1.31%. Jim Chanos suspects a major slowdown or distress.
No Data
No Data available this quarter, please select a different quarter.
-10.36%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
24.73%
Above 1.5x Medical - Pharmaceuticals median 1.38%. Jim Chanos sees a big jump in net debt. Potential leverage red flag.